R&D | Arcede Pharma

Research and Development

Pipeline and project portfolio

The primary focus of the project portfolio is to develop new treatments for COPD and severe asthma

RESP9000

RCD405–Drug candidate for the treatment of COPD and asthma

RESP9000, a compound series with for which a patent application was recently submitted, has demonstrated both anti-inflammatory and bronchodilatory properties equivalent to those of RESP1000, but is completely outside these compound series with respect to patents. The selected lead candidate, RCD405, is in preclinical phase and is the company’s prioritised project for development of new medications for treatment of COPD and severe asthma.

RESP9000, a compound series for which patent applications have been submitted. Patents have been granted in several European countries.

RESP3000

For diagnosis of cardiovascular disease

RESP3000 is a project aimed at diagnosing conditions such as cardiovascular diseases using PET imaging. No active research or development of this project is being pursued.

RESP1000

For the treatment of COPD and asthma

RESP1000 is a compound series of drug candidates with bronchodilatory and anti-inflammatory properties for the treatment of both COPD and asthma. No active research or development is being pursued.

Patents for RESP1000 have been granted in several countries.